Definition

  • Target the CYP17A1 enzyme (17α-hydroxylase and 17,20-lyase) to block androgen production in testes, adrenal glands, and tumor tissue.
  • Unlike ADT via LHRH analogs/antagonists (which only suppress testicular androgens), these agents also reduce extragonadal androgen production.

Main Agent in Clinical Use

Abiraterone acetate (Zytiga®, Yonsa®)

Mechanism of Action

  • CYP17A1 inhibition → ↓ androgen precursors (DHEA, androstenedione) → ↓ testosterone and DHT levels.
  • Also decreases glucocorticoid synthesis → ↑ ACTH → mineralocorticoid excess (fluid retention, hypertension, hypokalemia).

Dosing & Administration

  • Standard dose: Abiraterone acetate 1000 mg PO once daily (on empty stomach) + prednisone 5 mg PO BID (Zytiga®) or 5 mg daily (Yonsa® has different bioavailability).
  • Continue concurrent ADT (LHRH agonist/antagonist or orchiectomy).
  • Take ≥1 hour before or 2 hours after meals (food increases absorption up to 10-fold).

Adverse Effects

  • Mineralocorticoid excess: Hypertension, hypokalemia, edema.
  • Hepatotoxicity: ↑ AST/ALT; rare fulminant hepatic failure.
  • Fatigue, arthralgia, diarrhea.
  • Cardiac: Fluid overload, arrhythmias (use caution in CHF).
  • Other: Hot flashes, cough.

Monitoring

Parameter Frequency
LFTs (AST/ALT, bilirubin) Baseline, every 2 weeks × 3 months, then monthly
BP, potassium Baseline, monthly (more often if high risk)
PSA, testosterone Every 1–3 months
Signs of fluid overload Each visit
 
Drug Interactions
  • CYP3A4 substrate – avoid strong inhibitors/inducers.
  • Moderate inhibitor of CYP2D6 – may ↑ exposure to CYP2D6 substrates (e.g., some β-blockers, SSRIs, opioids).
  • Avoid with food due to ↑ absorption risk.

Special Populations

  • Hepatic impairment:
    • Child-Pugh B: Reduce dose to 250 mg daily.
    • Child-Pugh C: Avoid use.
  • Renal impairment: No dose adjustment for mild/moderate; limited data in severe.
  • Pregnancy: Contraindicated.

Practice Pearls

  • Prednisone is essential to prevent mineralocorticoid excess and adrenal insufficiency.
  • Counsel on empty stomach requirement.
  • For patients with uncontrolled hypertension, hypokalemia, or CHF, stabilize first before starting.
  • Continue ADT to maintain castrate testosterone levels.

Key Takeaway:

Androgen synthesis inhibitors like abiraterone complement ADT by blocking extra-testicular androgen production, improving survival in both hormone-sensitive and castration-resistant prostate cancer. Close monitoring for hepatic toxicity, mineralocorticoid excess, and drug interactions is essential for safe use.